Servier adds a 'smile' to its brand while setting ambitious oncology goals
Servier has dropped billions of dollars over the past several years with the goal of becoming a top player in hard-to-treat cancers. Now it’s setting a deadline — and giving its brand a makeover.
The French pharma aims to hit at least $2.9 billion (€3 billion) in annual oncology sales by 2030, an ambitious goal considering the group’s total revenue for the 2020/2021 fiscal year topped out at $4.6 billion (€4.725 billion). Servier launched a private US branch to focus on cancer back in 2018 dubbed Servier Pharmaceuticals, just after sweeping up Shire’s oncology business for $2.4 billion. A few years later, the company threw down $1.8 billion to take Agios’ Tibsovo and other cancer candidates into the fold.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
